Human antibodies to bone morphogenetic protein 6
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSarah J. Hatsell, Vincent J. Idone, Andrew J. Murphy
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.
Claims14
An isolated human monoclonal antibody or antigen-binding fragment thereof that binds specifically to human bone morphogenetic protein 6 (BMP6),
- wherein the antibody or antigen-binding fragment comprises:
- (i)
- (a) a heavy chain complementarity determining region (HCDR) 1 domain comprising SEQ ID NO:
- 5;
- (b) a HCDR2 domain comprising SEQ ID NO:
- 6;
- (c) a HCDR3 domain comprising SEQ ID NO:
- 7;
- (d) a light chain complementarity determining region (LCDR) 1 domain comprising SEQ ID NO:
- 8;
- (e) a LCDR2 domain comprising SEQ ID NO:
- 9;
- and
- (f) a LCDR3 domain comprising SEQ ID NO:
- 10;
- or
- (ii)
- (a) a HCDR1 domain comprising SEQ ID NO:
- 11;
- (b) a HCDR2 domain comprising SEQ ID NO:
- 12;
- (c) a HCDR3 domain comprising SEQ ID NO:
- 13;
- (d) a LCDR 1 domain comprising SEQ ID NO:
- 14;
- (e) a LCDR2 domain comprising SEQ ID NO:
- 15;
- and
- (f) a LCDR3 domain comprising SEQ ID NO:
- 16.
Dependencies are inferred from the claim text.